Boris Shor
Pfizer (United States)(US)Immune Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, HER2/EGFR in Cancer Research, Protein Kinase Regulation and GTPase Signaling, Monoclonal and Polyclonal Antibodies Research, RNA and protein synthesis mechanisms
Most-Cited Works
- → Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin(2009)326 cited
- → Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2(2010)208 cited
- → Requirement of the mTOR Kinase for the Regulation of Maf1 Phosphorylation and Control of RNA Polymerase III-dependent Transcription in Cancer Cells(2010)183 cited
- → Targeting mTOR globally in cancer: Thinking beyond rapamycin(2009)155 cited
- → Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies(2014)142 cited
- → A New Pharmacologic Action of CCI-779 Involves FKBP12-Independent Inhibition of mTOR Kinase Activity and Profound Repression of Global Protein Synthesis(2008)120 cited
- → Monoclonal antibody-based therapies in cancer: Advances and challenges(2013)116 cited
- → Cpc2/RACK1 Is a Ribosome-associated Protein That Promotes Efficient Translation in Schizosaccharomyces pombe(2003)87 cited
- → Cytotoxic Spliceostatins from Burkholderia sp. and Their Semisynthetic Analogues(2014)65 cited
- → Cpc2, a Fission Yeast Homologue of Mammalian RACK1 Protein, Interacts with Ran1 (Pat1) Kinase To Regulate Cell Cycle Progression and Meiotic Development(2000)61 cited